Featured Research

from universities, journals, and other organizations

Diagnosis Of Cutaneous Leishmaniasis Improved With New Techniques

Date:
January 29, 2008
Source:
Netherlands Organization for Scientific Research
Summary:
Scientists have developed and evaluated new techniques for a better diagnosis of cutaneous leishmaniasis and an improved monitoring of its treatment. Accurately establishing the number of parasites in a skin lesion before, during and after treatment is vital, so as to prevent serious physical consequences.

Dutch researcher Wendy van der Meide has developed and evaluated new techniques for a better diagnosis of cutaneous leishmaniasis and an improved monitoring of its treatment. Accurately establishing the number of parasites in a skin lesion before, during and after treatment is vital, so as to prevent serious physical consequences.

Cutaneous leishmaniasis (CL) is a non-lethal disease but can have grave consequences for the patient. Such consequences can be prevented with a rapid and accurate diagnosis and treatment. The treatment is based on clinical criteria. Therefore, it is essential to establish the number of parasites present in a skin lesion as accurately as possible before, during and after treatment in order to assess the treatment outcome.

Van der Meide has developed and evaluated a technique for the detection and quantification of Leishmania parasites. The so-called QT-NASBA technique, based on recognition of nucleic acids of the parasite, was found to be a sensitive and specific tool for monitoring treatments. The instrument can also contribute to predicting the clinical outcome. Although QT-NASBA was highly sensitive, another technique, the so-called real-time Reverse Transcriptase PCR was found to be more suitable due to its greater time efficiency and lower costs.

In practice, neither of these two techniques will be quickly deployed in developing countries. Therefore, different antigens were also compared in a serological test (ELISA) for use in Brazil and Suriname, where the disease is mainly caused by Leishmania guyanensis. The use of antigens for this species of Leishmania significantly improved the serological test compared to antigens from other species. These results could be vitally important for improving the effectiveness of serological tests for the diagnosis of CL.

Part of the research was carried out in Suriname. Van der Meide discovered that the prescribed treatment was only carried out to completion in a low percentage of cases; just half of the CL patients received the full treatment. Moreover, fewer patients seemed to recover than had previously been observed. Consequently, a shorter and more efficient treatment protocol was recommended to improve the use and efficacy of the treatment. Furthermore, it was demonstrated that not one but three different species of Leishmania in Suriname can cause human infection.

Parasites

Leishmaniasis is an infectious disease caused by single-celled parasites transmitted by sand flies. The disease occurs in tropical regions in Africa, Asia and America but also in the Mediterranean region and in the Middle East. Worldwide there is a clear and disturbing increase in the number of CL patients. CL results in one or more skin sores, and in the case of L. guyanensis regularly spreads into the lymph vessels. Although the sores can spontaneously disappear over the course of several months or years, they leave severe scars behind. Some types of CL can spread into the mucous membranes. This can lead to considerable damage of the nose cartilage and mouth.


Story Source:

The above story is based on materials provided by Netherlands Organization for Scientific Research. Note: Materials may be edited for content and length.


Cite This Page:

Netherlands Organization for Scientific Research. "Diagnosis Of Cutaneous Leishmaniasis Improved With New Techniques." ScienceDaily. ScienceDaily, 29 January 2008. <www.sciencedaily.com/releases/2008/01/080124104448.htm>.
Netherlands Organization for Scientific Research. (2008, January 29). Diagnosis Of Cutaneous Leishmaniasis Improved With New Techniques. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2008/01/080124104448.htm
Netherlands Organization for Scientific Research. "Diagnosis Of Cutaneous Leishmaniasis Improved With New Techniques." ScienceDaily. www.sciencedaily.com/releases/2008/01/080124104448.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins